3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
X-Rays
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Filgrastim
4
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Vorinostat
2
Topotecan
2
Psychiatric Rehabilitation
2
Peripheral Blood Stem Cell Transplantation
2
LY3023414
2
Etoposide
2
Cyproheptadine
2
Carboplatin
2
Bortezomib
2
trioctyl phosphine oxide
1
trametinib
1
sonidegib
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Medulloblastoma
×
bempegaldesleukin
×
Lymphoid
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts